Slide set providing a comprehensive overview of MC, covering everything from the structure of the colon through to MC subtypes and recommended treatments.
A single page outlining the facts about corticosteroids when treating inflammation. It explains to HCPs how the likelihood of side effects are reduced when treating MC with budesonide.
A MIMS learning module which HCPs can take to expand their knowledge on MC. The course aims to improve recognition of risk factors and key features of patient history while highlighting the potential misdiagnosis that can occur between irritable bowel syndrome and MC.
A MIMS learning module which HCPs can take to expand their knowledge on MC. The course includes a review of patient cases suggestive of MC, how to know when to investigate further, and treatment options for different situations.
A paper providing an overview of MC. It covers the epidemiology, risk factors, symptoms, diagnosis and management of MC. Budesonide is identified as the first-line treatment based on evidence from randomised controlled trials.
A paper which provides “a practical overview for the gastroenterologist looking after patients with MC”. The study contains a subsection on budesonide tolerability as well as images of characteristic histologic and colonoscopic findings.
A literary review which provides guidelines from the European Microscopic Colitis Group about the risk factors and epidemiology of MC, and recommendations for diagnostic criteria and treatment options.
A paper which evaluates the safety and efficacy of oral budesonide. The review discusses oral budesonide in the treatment of various conditions including MC.
A paper outlining why MC is often undiagnosed and measures that can be taken to reduce misdiagnoses. It highlights why many MC cases are initially treated as IBS under current NHS guidelines.
A lecture by Professor Chris Probert from the University of Liverpool. In 17 minutes he discusses the clinical descriptions, diagnosis, risk factors, treatments, and long-term therapy of MC. He also covers the potential of biologics as an alternative treatment to budesonide.